Published in Journal of Trauma and Acute Care Surgery · View the paper (DOI)
A team of researchers suggests using a drug commonly used for blood clots, tissue plasminogen activator (tPA), to help Covid-19 patients with severe respiratory distress. The approach is based on emerging data from China and Italy showing a disorder of blood clotting contributing to respiratory failure.
Coverage from 2 institutions
- A stopgap measure to treat respiratory distress Massachusetts Institute of Technology · Mar 25, 2020 · first to report
- Clinical trial to assess potential treatment for COVID-19-related respiratory failure Beth Israel Deaconess Medical Center · Apr 6, 2020